{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:01:10Z","timestamp":1782205270510,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00277-025-06475-y","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T08:43:59Z","timestamp":1754124239000},"page":"3917-3927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The evaluation, management, and future of indolent systemic mastocytosis"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0793-5560","authenticated-orcid":false,"given":"Arjun","family":"Syal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"McInerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-6953","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"issue":"20","key":"6475_CR1","doi-asserted-by":"publisher","first-page":"10885","DOI":"10.3390\/ijms252010885","volume":"25","author":"D Cilloni","year":"2024","unstructured":"Cilloni D, Maffeo B, Savi A, Danzero AC, Bonuomo V, Fava C (2024) Detection of KIT mutations in systemic mastocytosis: How When, and Why. Int J Mol Sci 25(20):10885. https:\/\/doi.org\/10.3390\/ijms252010885","journal-title":"Int J Mol Sci"},{"key":"6475_CR2","doi-asserted-by":"publisher","unstructured":"Khoury JD et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"4","key":"6475_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"112","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe DD (2008) Mast cells and mastocytosis. Blood 112(4):946\u2013956. https:\/\/doi.org\/10.1182\/blood-2007-11-078097","journal-title":"Blood"},{"issue":"23","key":"6475_CR4","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/cancers15235626","volume":"15","author":"JY Li","year":"2023","unstructured":"Li JY et al (2023) Review and updates on systemic mastocytosis and related entities. Cancers (Basel) 15(23):5626. https:\/\/doi.org\/10.3390\/cancers15235626","journal-title":"Cancers (Basel)"},{"key":"6475_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jdcr.2023.04.009","volume":"36","author":"ML Paiva","year":"2023","unstructured":"Paiva ML, Yumeen S, Saliba E, DiMarco C (2023) Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches. JAAD Case Rep 36:63\u201366. https:\/\/doi.org\/10.1016\/j.jdcr.2023.04.009","journal-title":"JAAD Case Rep"},{"issue":"4","key":"6475_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS et al (2014) Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166(4):521\u2013528. https:\/\/doi.org\/10.1111\/bjh.12916","journal-title":"Br J Haematol"},{"issue":"5","key":"6475_CR7","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1016\/j.anai.2023.08.560","volume":"131","author":"A Khalid","year":"2023","unstructured":"Khalid A, Faiz A, Pappu A, Pakanati A (2023) Indolent systemic mastocytosis: an incidental diagnosis. Ann Allergy Asthma Immunol 131(5):S182. https:\/\/doi.org\/10.1016\/j.anai.2023.08.560","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"16","key":"6475_CR8","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.3390\/cancers14163942","volume":"14","author":"J Ungerstedt","year":"2022","unstructured":"Ungerstedt J, Ljung C, Klimkowska M, G\u00fclen T (2022) Clinical outcomes of adults with systemic mastocytosis: A 15-year multidisciplinary experience. Cancers (Basel) 14(16):3942. https:\/\/doi.org\/10.3390\/cancers14163942","journal-title":"Cancers (Basel)"},{"issue":"11","key":"6475_CR9","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/ajh.27478","volume":"99","author":"M Heiblig","year":"2024","unstructured":"Heiblig M et al (2024) Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin. Am J Hematol 99(11):2127\u20132139. https:\/\/doi.org\/10.1002\/ajh.27478","journal-title":"Am J Hematol"},{"issue":"4","key":"6475_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.iac.2023.04.004","volume":"43","author":"SS Ellingwood","year":"2023","unstructured":"Ellingwood SS, Kovalszki A (2023) Effect of gender and special considerations for women in mastocytosis and anaphylaxis. Immunol Allergy Clin North Am 43(4):763\u2013776. https:\/\/doi.org\/10.1016\/j.iac.2023.04.004","journal-title":"Immunol Allergy Clin North Am"},{"key":"6475_CR11","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2018-99-120192","volume":"132","author":"A Bista","year":"2018","unstructured":"Bista A et al (2018) Systemic mastocytosis in united states: a population based study. Blood 132:1830. https:\/\/doi.org\/10.1182\/blood-2018-99-120192","journal-title":"Blood"},{"issue":"11","key":"6475_CR12","doi-asserted-by":"publisher","first-page":"100838","DOI":"10.1016\/j.waojou.2023.100838","volume":"16","author":"P Pyatilova","year":"2023","unstructured":"Pyatilova P et al (2023) The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey. World Allergy Organ J 16(11):100838. https:\/\/doi.org\/10.1016\/j.waojou.2023.100838","journal-title":"World Allergy Organ J"},{"issue":"4","key":"6475_CR13","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jacig.2024.100316","volume":"3","author":"KY Tse","year":"2024","unstructured":"Tse KY et al (2024) MASTering systemic mastocytosis: Lessons learned from a large patient cohort. J Allerg Clin Immunol Global 3(4):100316. https:\/\/doi.org\/10.1016\/j.jacig.2024.100316","journal-title":"J Allerg Clin Immunol Global"},{"issue":"16","key":"6475_CR14","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","volume":"121","author":"A Pardanani","year":"2013","unstructured":"Pardanani A (2013) How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 121(16):3085\u20133094. https:\/\/doi.org\/10.1182\/blood-2013-01-453183","journal-title":"Blood"},{"issue":"3","key":"6475_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","volume":"67","author":"E van der Veer","year":"2012","unstructured":"van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67(3):431\u2013438. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02780.x","journal-title":"Allergy"},{"issue":"23","key":"6475_CR16","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"K-H Lim","year":"2009","unstructured":"Lim K-H et al (2009) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113(23):5727\u20135736. https:\/\/doi.org\/10.1182\/blood-2009-02-205237","journal-title":"Blood"},{"issue":"4","key":"6475_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jaip.2020.12.022","volume":"9","author":"D Fuchs","year":"2021","unstructured":"Fuchs D et al (2021) Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. J Allergy Clin Immunol Pract 9(4):1705-1712.e4. https:\/\/doi.org\/10.1016\/j.jaip.2020.12.022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"6475_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11914-025-00901-w","volume":"23","author":"Y Degbo\u00e9","year":"2025","unstructured":"Degbo\u00e9 Y, Nezzar C, Alary P, Ma\u00ebva M, Bulai Livideanu C, Laroche M (2025) Management of bone health in adult mastocytosis. Curr Osteoporos Rep 23(1):10. https:\/\/doi.org\/10.1007\/s11914-025-00901-w","journal-title":"Curr Osteoporos Rep"},{"issue":"8","key":"6475_CR19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","volume":"28","author":"M Jara-Acevedo","year":"2015","unstructured":"Jara-Acevedo M et al (2015) Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Modern Pathol 28(8):1138\u20131149. https:\/\/doi.org\/10.1038\/modpathol.2015.72","journal-title":"Modern Pathol"},{"issue":"5","key":"6475_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood.2018886507","volume":"134","author":"JI Mu\u00f1oz-Gonz\u00e1lez","year":"2019","unstructured":"Mu\u00f1oz-Gonz\u00e1lez JI et al (2019) Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood 134(5):456\u2013468. https:\/\/doi.org\/10.1182\/blood.2018886507","journal-title":"Blood"},{"key":"6475_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13223-017-0193-x","volume":"13","author":"I Conde-Fernandes","year":"2017","unstructured":"Conde-Fernandes I et al (2017) Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome. Allergy Asthma Clin Immunol 13:21. https:\/\/doi.org\/10.1186\/s13223-017-0193-x","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"6475_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jaci.2013.12.1090","volume":"134","author":"EC Chan","year":"2014","unstructured":"Chan EC et al (2014) Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol 134(1):178\u2013187. https:\/\/doi.org\/10.1016\/j.jaci.2013.12.1090","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"6475_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1586\/17474086.2014.955008","volume":"7","author":"P Valent","year":"2014","unstructured":"Valent P et al (2014) The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol 7(5):683\u2013690. https:\/\/doi.org\/10.1586\/17474086.2014.955008","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"6475_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaci.2022.09.038","volume":"151","author":"B Sordi","year":"2023","unstructured":"Sordi B et al (2023) Disease correlates and clinical relevance of hereditary \u03b1-tryptasemia in patients with systemic mastocytosis. J Allergy Clin Immunol 151(2):485-493.e11. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.038","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"6475_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.2020006157","volume":"137","author":"G Greiner","year":"2021","unstructured":"Greiner G et al (2021) Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood 137(2):238\u2013247. https:\/\/doi.org\/10.1182\/blood.2020006157","journal-title":"Blood"},{"issue":"6","key":"6475_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.anai.2021.08.009","volume":"127","author":"SC Glover","year":"2021","unstructured":"Glover SC et al (2021) Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond. Ann Allergy Asthma Immunol 127(6):638\u2013647. https:\/\/doi.org\/10.1016\/j.anai.2021.08.009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"6475_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-136930","volume":"136","author":"TI George","year":"2020","unstructured":"George TI, Hoehn G, Lin H-M, Miller S, Akin C (2020) Increased detection of KIT D816V mutation in peripheral blood samples from patients with Indolent Systemic Mastocytosis (ISM) in the phase 2 pioneer study using a high sensitivity droplet digital (dd) PCR assay compared with Next Generation Sequencing (NGS). Blood 136:7\u20138. https:\/\/doi.org\/10.1182\/blood-2020-136930","journal-title":"Blood"},{"issue":"Supplement 1","key":"6475_CR28","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1182\/blood-2024-207798","volume":"144","author":"DH Radia","year":"2024","unstructured":"Radia DH et al (2024) Ultra-sensitive KIT testing uncovers previously undetected kit mutations in patients with indolent systemic mastocytosis: results from the pioneer trial. Blood 144(Supplement 1):3164\u20133164. https:\/\/doi.org\/10.1182\/blood-2024-207798","journal-title":"Blood"},{"issue":"12","key":"6475_CR29","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","volume":"16","author":"J Gotlib","year":"2018","unstructured":"Gotlib J et al (2018) Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(12):1500\u20131537. https:\/\/doi.org\/10.6004\/jnccn.2018.0088","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"6475_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3324\/haematol.2019.217950","volume":"105","author":"G Greiner","year":"2020","unstructured":"Greiner G et al (2020) Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. Haematologica 105(2):366\u2013374. https:\/\/doi.org\/10.3324\/haematol.2019.217950","journal-title":"Haematologica"},{"issue":"3","key":"6475_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000329856","volume":"157","author":"I Alvarez-Twose","year":"2012","unstructured":"Alvarez-Twose I et al (2012) Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 157(3):275\u2013280. https:\/\/doi.org\/10.1159\/000329856","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"6475_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/all.12159","volume":"68","author":"F Siebenhaar","year":"2013","unstructured":"Siebenhaar F et al (2013) Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 68(7):949\u2013952. https:\/\/doi.org\/10.1111\/all.12159","journal-title":"Allergy"},{"issue":"5","key":"6475_CR33","first-page":"E30","volume":"99","author":"Z Husain","year":"2017","unstructured":"Husain Z, Waterman D, Ellison K, DeSimone JA (2017) Management of poorly controlled indolent systemic mastocytosis using narrowband UVB phototherapy. Cutis 99(5):E30-e33","journal-title":"Cutis"},{"issue":"5\u20136","key":"6475_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/phpp.12248","volume":"32","author":"V Brazzelli","year":"2016","unstructured":"Brazzelli V et al (2016) Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed 32(5\u20136):238\u2013246. https:\/\/doi.org\/10.1111\/phpp.12248","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"5","key":"6475_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2796.1991.tb00379.x","volume":"229","author":"P P\u00f3voa","year":"1991","unstructured":"P\u00f3voa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG (1991) A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 229(5):475\u2013477. https:\/\/doi.org\/10.1111\/j.1365-2796.1991.tb00379.x","journal-title":"J Intern Med"},{"issue":"1","key":"6475_CR36","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1182\/blood-2018-99-120112","volume":"132","author":"CA Slapnicar","year":"2018","unstructured":"Slapnicar CA, Scullion Smeenk C, Hicks LK, Petrucci J, Vadas P, Trinkaus M (2018) A retrospective case series describing the efficacy of ketotifen in systemic mastocytosis. Blood 132(1):5474\u20135474. https:\/\/doi.org\/10.1182\/blood-2018-99-120112","journal-title":"Blood"},{"issue":"4","key":"6475_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/aci.0000000000000377","volume":"17","author":"T G\u00fclen","year":"2017","unstructured":"G\u00fclen T, Akin C (2017) Pharmacotherapy of mast cell disorders. Curr Opin Allergy Clin Immunol 17(4):295\u2013303. https:\/\/doi.org\/10.1097\/aci.0000000000000377","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"6475_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0002-9343(85)90454-1","volume":"78","author":"M Frieri","year":"1985","unstructured":"Frieri M, Alling DW, Metcalfe DD (1985) Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 78(1):9\u201314. https:\/\/doi.org\/10.1016\/0002-9343(85)90454-1","journal-title":"Am J Med"},{"issue":"5","key":"6475_CR39","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","volume":"85","author":"RF Horan","year":"1990","unstructured":"Horan RF, Sheffer AL, Austen KF (1990) Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 85(5):852\u2013855. https:\/\/doi.org\/10.1016\/0091-6749(90)90067-E","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"6475_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","volume":"14","author":"AS Worobec","year":"2000","unstructured":"Worobec AS (2000) Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 14(3):659\u2013687. https:\/\/doi.org\/10.1016\/S0889-8588(05)70301-4","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"6475_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.12788\/fp.0081","volume":"38","author":"SL Weiss","year":"2021","unstructured":"Weiss SL, Hyman JB, Carlson GS, Coop CA (2021) Long-term successful treatment of indolent systemic mastocytosis with omalizumab. Fed Pract 38(1):44\u201348. https:\/\/doi.org\/10.12788\/fp.0081","journal-title":"Fed Pract"},{"issue":"7","key":"6475_CR42","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal R et al (2019) Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract 7(7):2387-2395.e3. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.039","journal-title":"J Allergy Clin Immunol Pract"},{"key":"6475_CR43","unstructured":"Zaheer S, LeBoff MS (2022) Osteoporosis: prevention and treatment. In: Feingold KR, Ahmed SF, Anawalt B, et al. (eds) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279073\/"},{"issue":"6","key":"6475_CR44","doi-asserted-by":"publisher","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","volume":"2","author":"J Gotlib","year":"2023","unstructured":"Gotlib J et al (2023) Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evidence 2(6):EVIDoa2200339. https:\/\/doi.org\/10.1056\/EVIDoa2200339","journal-title":"NEJM Evidence"},{"issue":"3","key":"6475_CR45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","volume":"142","author":"B van Anrooij","year":"2018","unstructured":"van Anrooij B et al (2018) Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. J Allergy Clin Immunol 142(3):1006-1008.e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.003","journal-title":"J Allergy Clin Immunol"},{"issue":"Supplement 1","key":"6475_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2023-188904","volume":"142","author":"T Tashi","year":"2023","unstructured":"Tashi T et al (2023) Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: analysis of the harbor trial. Blood 142(Supplement 1):76\u201376. https:\/\/doi.org\/10.1182\/blood-2023-188904","journal-title":"Blood"},{"issue":"2","key":"6475_CR47","doi-asserted-by":"publisher","first-page":"AB340","DOI":"10.1016\/j.jaci.2022.12.795","volume":"151","author":"M Maurer","year":"2023","unstructured":"Maurer M et al (2023) Avapritinib improved skin findings in patients with Indolent Systemic Mastocytosis (ISM) in the registrational, double-blind, placebo controlled PIONEER study. J Allerg Clin Immunol 151(2):AB340. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.795","journal-title":"J Allerg Clin Immunol"},{"issue":"5","key":"6475_CR48","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.anai.2023.08.243","volume":"131","author":"P Ogbogu","year":"2023","unstructured":"Ogbogu P et al (2023) Avapritinib improved gastrointestinal symptoms in patients with indolent systemic mastocytosis: registrational double-blind, placebo-controlled pioneer study. Ann Allergy Asthma Immunol 131(5):S81. https:\/\/doi.org\/10.1016\/j.anai.2023.08.243","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"6475_CR49","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ et al (2021) Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183\u20132191. https:\/\/doi.org\/10.1038\/s41591-021-01538-9","journal-title":"Nat Med"},{"key":"6475_CR50","unstructured":"Sabato V, Gotlib J, Castells M, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Akin C, Bulai Livideanu C, Jurcic J, Oude Elberink H, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schafhausen P, Vadas P, Bose P, Maurer M, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Hartmann K, \u2026 Broesby-Olsen S (2024) Longer-term safety of avapritinib in indolent systemic mastocytosis: The phase 2 PIONEER study. Abstract presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Valencia, Spain"},{"issue":"40","key":"6475_CR51","doi-asserted-by":"publisher","first-page":"68950","DOI":"10.18632\/oncotarget.10711","volume":"8","author":"I Alvarez-Twose","year":"2017","unstructured":"Alvarez-Twose I et al (2017) Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget 8(40):68950\u201368963. https:\/\/doi.org\/10.18632\/oncotarget.10711","journal-title":"Oncotarget"},{"issue":"6","key":"6475_CR52","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3109\/09546634.2013.802274","volume":"24","author":"MK Agarwala","year":"2013","unstructured":"Agarwala MK, George R, Mathews V, Balasubramanian P, Thomas M, Nair S (2013) Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. J Dermatolog Treat 24(6):481\u2013483. https:\/\/doi.org\/10.3109\/09546634.2013.802274","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"6475_CR53","first-page":"93","volume":"4","author":"P Valent","year":"2014","unstructured":"Valent P et al (2014) Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. Am J Blood Res 4(2):93\u2013100","journal-title":"Am J Blood Res"},{"issue":"8","key":"6475_CR54","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/all.14248","volume":"75","author":"J Trizuljak","year":"2020","unstructured":"Trizuljak J et al (2020) Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy 75(8):1927\u20131938. https:\/\/doi.org\/10.1111\/all.14248","journal-title":"Allergy"},{"issue":"12","key":"6475_CR55","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/s2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr WR et al (2019) International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol 6(12):e638\u2013e649. https:\/\/doi.org\/10.1016\/s2352-3026(19)30166-8","journal-title":"Lancet Haematol"},{"issue":"2","key":"6475_CR56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaip.2022.10.051","volume":"11","author":"J L\u00fcbke","year":"2023","unstructured":"L\u00fcbke J et al (2023) Prognostic impact of organomegaly in mastocytosis: an analysis of the european competence network on mastocytosis. J Allergy Clin Immunol Pract 11(2):581-590.e5. https:\/\/doi.org\/10.1016\/j.jaip.2022.10.051","journal-title":"J Allergy Clin Immunol Pract"},{"key":"6475_CR57","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1017\/s146342362200024x","volume":"23","author":"K Hamberg Levedahl","year":"2022","unstructured":"Hamberg Levedahl K, Nilsson A, Johansson B, Hedstr\u00f6m M (2022) How persons with systemic mastocytosis describe the time between symptom onset and receiving diagnosis. Prim Health Care Res Dev 23:e54. https:\/\/doi.org\/10.1017\/s146342362200024x","journal-title":"Prim Health Care Res Dev"},{"issue":"9928","key":"6475_CR58","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/s0140-6736(14)60585-7","volume":"383","author":"T G\u00fclen","year":"2014","unstructured":"G\u00fclen T, H\u00e4gglund H, Dahl\u00e9n SE, Sander B, Dahl\u00e9n B, Nilsson G (2014) Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis. Lancet 383(9928):1608. https:\/\/doi.org\/10.1016\/s0140-6736(14)60585-7","journal-title":"Lancet"},{"issue":"4","key":"6475_CR59","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1182\/blood.2024024943","volume":"144","author":"J Rossignol","year":"2024","unstructured":"Rossignol J, Arock M (2024) Diagnosis of mastocytosis: emerging iceberg? Blood 144(4):350\u2013352. https:\/\/doi.org\/10.1182\/blood.2024024943","journal-title":"Blood"},{"issue":"Supplement 1","key":"6475_CR60","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2022-156311","volume":"140","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo DJ et al (2022) Preliminary safety and efficacy from apex, a phase 2 study of bezuclastinib (CGT9486), a novel, highly selective, potent KIT D816V Tyrosine Kinase inhibitor, in adults with advanced systemic mastocytosis (AdvSM). Blood 140(Supplement 1):1512\u20131513. https:\/\/doi.org\/10.1182\/blood-2022-156311","journal-title":"Blood"},{"issue":"Supplement 1","key":"6475_CR61","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1182\/blood-2024-194551","volume":"144","author":"LAM Rein","year":"2024","unstructured":"Rein LAM et al (2024) Updated efficacy and safety results of patients receiving selected 100mg Bezuclastinib dose and participating in the open-label extension of summit: a randomized, double-blind, placebo controlled phase 2 clinical trial of Bezuclastinib in adult patients with nonadvanced systemic mastocytosis. Blood 144(Supplement 1):4556\u20134556. https:\/\/doi.org\/10.1182\/blood-2024-194551","journal-title":"Blood"},{"issue":"Supplement 1","key":"6475_CR62","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1182\/blood-2021-152770","volume":"138","author":"A Guarnieri","year":"2021","unstructured":"Guarnieri A et al (2021) Preclinical data with KIT D816V inhibitor Bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance. Blood 138(Supplement 1):4595\u20134595. https:\/\/doi.org\/10.1182\/blood-2021-152770","journal-title":"Blood"},{"issue":"2","key":"6475_CR63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jaci.2024.12.538","volume":"155","author":"M Castells","year":"2025","unstructured":"Castells M et al (2025) HARBOR: an ongoing phase 2\/3 study of elenestinib in patients with indolent systemic mastocytosis. J Allergy Clin Immunol 155(2):170. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.538","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"6475_CR64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bjd\/ljad191","volume":"189","author":"F Siebenhaar","year":"2023","unstructured":"Siebenhaar F et al (2023) Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. Br J Dermatol 189(5):511\u2013519. https:\/\/doi.org\/10.1093\/bjd\/ljad191","journal-title":"Br J Dermatol"},{"issue":"10069","key":"6475_CR65","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/s0140-6736(16)31403-9","volume":"389","author":"O Lortholary","year":"2017","unstructured":"Lortholary O et al (2017) Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 389(10069):612\u2013620. https:\/\/doi.org\/10.1016\/s0140-6736(16)31403-9","journal-title":"Lancet"},{"key":"6475_CR66","unstructured":"A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed\/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis [Online] Available: https:\/\/clinicaltrials.gov\/study\/NCT04655118"},{"issue":"1","key":"6475_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2024.06.005","volume":"25","author":"HT Chifotides","year":"2025","unstructured":"Chifotides HT, Bose P (2025) SOHO state of the art update and next questions: current and emerging therapies for systemic mastocytosis. Clin Lymphoma Myeloma Leuk 25(1):1\u201312. https:\/\/doi.org\/10.1016\/j.clml.2024.06.005","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06475-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06475-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06475-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:49:10Z","timestamp":1757663350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06475-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6475"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06475-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DT receives contracted research funding paid to his institution from Sobi, Sumitomo, Cogent Biosciences and Gilead and consulting fees from Sobi, AbbVie, Pharmaessentia, Geron, GSK and Cogent Biosciences. The other authors have no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}